EP4743112A1 - ESCHERICHIA COLI NHAA MEMBRANE PROTEIN ACTIVE INGREDIENT TARGET AND IMMUNOGENIC COMPOSITIONS FROM IT - Google Patents

ESCHERICHIA COLI NHAA MEMBRANE PROTEIN ACTIVE INGREDIENT TARGET AND IMMUNOGENIC COMPOSITIONS FROM IT

Info

Publication number
EP4743112A1
EP4743112A1 EP23945745.0A EP23945745A EP4743112A1 EP 4743112 A1 EP4743112 A1 EP 4743112A1 EP 23945745 A EP23945745 A EP 23945745A EP 4743112 A1 EP4743112 A1 EP 4743112A1
Authority
EP
European Patent Office
Prior art keywords
nhaa
active ingredient
escherichia coli
membrane protein
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23945745.0A
Other languages
German (de)
French (fr)
Inventor
Ganwu Li
Haobo Zhang
Fengwei Jiang
Zhao Mao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Publication of EP4743112A1 publication Critical patent/EP4743112A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP23945745.0A 2023-07-14 2023-07-14 ESCHERICHIA COLI NHAA MEMBRANE PROTEIN ACTIVE INGREDIENT TARGET AND IMMUNOGENIC COMPOSITIONS FROM IT Pending EP4743112A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2023/057238 WO2025017339A1 (en) 2023-07-14 2023-07-14 Escherichia coli nhaa membrane protein drug target and immunogenic compositions therefrom

Publications (1)

Publication Number Publication Date
EP4743112A1 true EP4743112A1 (en) 2026-05-20

Family

ID=94281200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23945745.0A Pending EP4743112A1 (en) 2023-07-14 2023-07-14 ESCHERICHIA COLI NHAA MEMBRANE PROTEIN ACTIVE INGREDIENT TARGET AND IMMUNOGENIC COMPOSITIONS FROM IT

Country Status (2)

Country Link
EP (1) EP4743112A1 (en)
WO (1) WO2025017339A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2351772T1 (en) * 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US20110265221A1 (en) * 2007-07-10 2011-10-27 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits

Also Published As

Publication number Publication date
WO2025017339A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
IL288204A (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
EP4624467A3 (en) Protein degraders and uses thereof
JP2018502600A5 (en)
MX2021004331A (en) STABLE COMPOSITIONS OF SEMAGLUTIDE AND THEIR USES.
CY1118930T1 (en) RECONSTRUCTIONED PROTECTION PROTEINS AND METHODS OF INDUSTRIAL CONSTRUCTION AND USE
WO2018155813A3 (en) Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium
EP4230041A4 (en) HERBICIDAL COMPOSITION, PREPARATION, AND ITS APPLICATION
EA201990856A1 (en) NEW ANTI-MICROBIAL AGENTS AGAINST ENTEROCOCCUS BACTERIA
LT4135523T (en) ACTIVE COMBINATIONS OF COMPOUNDS AND FUNGICIDAL COMPOSITIONS COMPRISING THEM
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
EA202090536A1 (en) CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4-OXADIAZOL
WO2020021108A3 (en) Nucleic acids for inhibiting expression of tmprss6 and iron chelators
EP3999043A4 (en) PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS
BR112022005782A2 (en) RECOMBINANT STABILIZED GALECTIN 9 PROTEIN, RECOMBINANT, TRANSFORMING VECTOR, PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A BONE DISEASE, FUNCTIONAL HEALTH FOOD FOR THE PREVENTION OR IMPROVEMENT OF A BONE DISEASE, AND, USE OF A RECOMBINANT STABILIZED GALECTIN 9 PROTEIN
EP3802573A4 (en) COMPOSITION OF VACCINE COMPRISING RECOMBINANT PROTEIN OF ATTENUED ENTEROTOXIN AND CYTOTOXIN OF STAPHYLOCOCCUS AUREUS
EP4422615A4 (en) Compositions of stable metformin and similar active ingredient products with control of nitroso impurities
DK4138807T3 (en) CO-CRYSTALS OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE
EP4208198A4 (en) Recombinant SARS-CoV-2 spike protein subunits, expression, and uses thereof
EP3763228C0 (en) COMPOSITION CONTAINING A COMBINATION OF PLANT PROTEINS AND PEPTIDES
MX2019014697A (en) Rage proteins for the treatment of fibrosis and dna damage mediated diseases.
BR112019024796A2 (en) PEPTIDES AND USES OF THE SAME AS ANTI-VIRAL AGENTS
MY184807A (en) Insecticidal incense formulation composition, method of manufacture and applications thereof
BR112018012451A2 (en) virus-based biopesticide
MX2023010928A (en) FORMULATIONS THAT COMPRISE A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER.
EA202191368A1 (en) HERBICIDE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE